The FDA’s Commissioner’s National Priority Voucher pilot program was built for speed. Since launching in June 2025, it has awarded more than 22 vouchers and delivered seven approvals, compressing standard 10-12 month timelines to as little as 44 days (for Boehringer Ingelheim’s Hernexeos).But the FDA’s first public hearing on the program, held June 4 at White Oak, sent a clear signal: speed alone will not protect this program from a legitimacy crisis.

What the Hearing Revealed

Seventeen speakers from patient groups, industry and academia addressed the agency. Most supported faster access in principle — and most called for a pause. Even stakeholders sympathetic to the program’s mission asked FDA to halt activity in the program, rebuild the framework through formal notice-and-comment rulemaking, and restart reviews on solid legal ground.

Three criticisms dominated the hearing.

First, the selection process is opaque. FDA had not, as of the June 4 hearing, published criteria explaining who qualifies for a CNPV review or why. PhRMA warned that the program’s durability depends on transparency and predictability.

Second, the compressed review window has drawn persistent questions about scientific rigor. Critics have raised these concerns even under the FDA’s multidisciplinary tumor board model, though FDA has not formally responded to them on the record.

Third, the program’s structure has drawn warnings about political vulnerability. Peter Lurie, a former FDA associate commissioner and head of CSPI, argued that the review board’s direct line to the Commissioner makes it inherently susceptible to political pressure, calling for the program to be shut down.

The rejection of Disc Medicine’s bitopertin in February offers an important counterpoint. The drug secured expedited CNPV review and still received a complete response letter, with reviewers citing Disc’s phase 2 trial relying on a surrogate endpoint rather than clinical outcomes.

That rejection represents the program’s strongest argument for scientific integrity: speed changes the clock, not the evidentiary standard. But it hasn’t resolved questions about how products are selected for the pathway.

What This Means for the Program’s Future

Last week’s hearing sharpened the risk without resolving it. Critics across the spectrum — from PhRMA to public-interest watchdogs — have called for the same thing: rules. As of the hearing date, the program had not published codified eligibility criteria or established a formal appeals process, a gap that drew criticism from stakeholders across the political spectrum.

Whether the CNPV operates with or without statutory authority is a legal question being actively debated. Multiple stakeholders at the hearing argued it lacks such authority — a characterization FDA has neither publicly disputed nor formally addressed. The most credible path forward, in the view of program supporters and critics alike, is codification through PDUFA reauthorization or formal rulemaking that establishes clear standards and a defined review structure. Without that, the program remains a political and legal target — one a future administration could reshape or eliminate.

If you have a CNPV approval in hand, the program’s vulnerability is your vulnerability. A 50-day approval under a program whose legal framework remains unsettled isn’t automatically suspect, but it will face scrutiny the standard pathways do not invite. It’s not prudent to wait for Congress or FDA to resolve this. Build and communicate your evidentiary case now — independent of what happens to the CNPV pilot.

1. Publish the science — and make it usable. Labels and press releases aren’t enough. Release clinical summaries, package-insert details and available study data in formats physicians, payers and policymakers can actually use. A transparent evidentiary record is the most effective counter to any ‘political approval’ narrative. If your data is strong, visibility is protection.
2. Pursue international regulatory validation — and publicize it. Parallel review or approval by EMA, MHRA or Health Canada provides independent confirmation under entirely different legal and political systems. Examples such as Boehringer Ingelheim’s NMPA approval for Hernexeos and Regeneron’s Otarmeni (which according to company-published CHORD trial data shows 80% of patients achieving measurable hearing improvement) demonstrate how a compelling global evidence story insulates a product from domestic political uncertainty.
3. Generate and deploy real-world evidence aggressively. Post-market data is the most durable proof of value — and the hardest to dismiss. Launch registries early. Commission HEOR analyses. Publish post-marketing commitment data broadly across clinical, policy and investor audiences. If the pathway is later challenged, your product’s credibility must rest on real-world outcomes — not on how fast it was reviewed.
4. Build your patient and KOL coalition before PDUFA negotiations end in 2027. PDUFA reauthorization is the most realistic path to codifying the CNPV into durable law —  but only if the right voices speak up to defend it. Patients who experienced meaningful benefit and physicians who observed it firsthand are the program’s most credible validators with Congress. For companies that want to preserve this expedited pathway, identifying and engaging those advocates now will be critical to formally define eligibility standards and review structure through reauthorization. Additionally, such advocacy can spur FDA to incorporate elements of the CNPV approach into other existing pathways.

The CNPV may survive, be codified in a stronger form or be eliminated. What won’t change is the scrutiny applied to every product it approved. Companies that build an independent evidentiary foundation now — before the political and legal environment forces the question — will be far better positioned regardless of outcome.

The CNPV’s legitimacy question is structural, not scientific. The program outran its own governance, and the products approved through it now carry that exposure. This is a communications and policy challenge as much as a regulatory one — and it requires an integrated response.

To stay ahead of these issues, companies should be thinking about evidence generation, global regulatory strategy and stakeholder communications as one coordinated effort. Scientific credibility built in Washington is reinforced by regulatory endorsement from London or Ottawa. Payer confidence comes from HEOR data, not approval speed. Physician trust is earned through transparency about what the review did — and did not — evaluate.

The question is not whether a CNPV product can withstand scrutiny; it’s whether companies are building the case that proves it.

— Leslie Isenegger, Head of Growth & Strategy, RC Resolve